Search Videos and More

Showing 1 - 6 of 6 results

Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer News

Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.
New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer News

New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer

Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guideline
Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma News

Dana-Farber Leads Adaptive, Efficient Multi-arm Phase 2 Clinical Trial for Glioblastoma

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology.
AI-Driven Muscle Mass Assessment Could Improve Care for Head and Neck Cancer Patients News

AI-Driven Muscle Mass Assessment Could Improve Care for Head and Neck Cancer Patients

Researchers from Dana-Farber Cancer Institute have found a way to use artificial intelligence (AI) to diagnose muscle wasting, called sarcopenia, in patients with head and neck cancer.
ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD Video

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD

Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.
Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades News

Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades

In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.